These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38328923)

  • 1. The association between atherogenic index of plasma and metabolic dysfunction-associated fatty liver disease as detected by FibroScan.
    Wang A; Li J; Li L; Ding H; Yang N; Xu M
    Nutr Hosp; 2024 Apr; 41(2):384-392. PubMed ID: 38328923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018.
    Chen Y; Lu C; Ju H; Zhou Q; Zhao X
    Front Endocrinol (Lausanne); 2024; 15():1405828. PubMed ID: 38808115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
    Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
    Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association with the plasma atherogenic index with hepatic steatosis and fibrosis in the US population.
    Li Y; Men X; Liu Y; Jiang H; Bi C; Qu Y; Wang K; Wang X; Jing J; Liu Y
    Medicine (Baltimore); 2024 Feb; 103(8):e37152. PubMed ID: 38394523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
    Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
    Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease.
    Duan SJ; Ren ZY; Zheng T; Peng HY; Niu ZH; Xia H; Chen JL; Zhou YC; Wang RR; Yao SK
    World J Gastroenterol; 2022 Sep; 28(36):5364-5379. PubMed ID: 36185625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Hepatol Commun; 2022 Aug; 6(8):2070-2078. PubMed ID: 35470984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound and FibroScan
    Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
    Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
    Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
    Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
    Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
    Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
    Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the cardiometabolic index and NAFLD and fibrosis.
    Yan L; Hu X; Wu S; Cui C; Zhao S
    Sci Rep; 2024 Jun; 14(1):13194. PubMed ID: 38851771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter.
    Marc L; Mihaescu A; Lupusoru R; Grosu I; Gadalean F; Bob F; Chisavu L; Olariu N; Tucicovschi V; Timar B; Sporea I; Timar R; Schiller A
    Front Med (Lausanne); 2021; 8():788881. PubMed ID: 35096879
    [No Abstract]   [Full Text] [Related]  

  • 17. Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: A cross-sectional study.
    Du R; Tang XY; Yang C; Gao WH; Gao SJ; Xiang HJ; Yang L
    PLoS One; 2023; 18(5):e0284859. PubMed ID: 37200309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.
    Samimi S; Rajabzadeh S; Rabizadeh S; Nakhjavani M; Nakhaei P; Avanaki FA; Esteghamati A
    Eur J Med Res; 2022 Jul; 27(1):112. PubMed ID: 35818084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
    Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
    Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017-2018.
    Tian T; Zhang J; Xie W; Ni Y; Fang X; Liu M; Peng X; Wang J; Dai Y; Zhou Y
    Nutrients; 2022 Oct; 14(21):. PubMed ID: 36364767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.